Guangzhou Kingmed Diagnostics Group Co. Ltd. Class A

Guangzhou Kingmed Diagnostics Group Co. Ltd. Class A

SSSE:603882
27.48
CNY
+1.10
(+4.17%)
0.69EPS
48.07P/E
13.46BMarket Cap
Apr 26Next Earn
Guangzhou Kingmed Diagnostics Group Co. Ltd. Class A
SSE:603882
(Shanghai Stock Exchange)

Recent

price

27.48

P/E

ratio

48.07

div

yld

3.27%

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
49.48
68.67
4.01
6.91
8.34
9.25
9.89
11.53
17.97
25.83
33.2
18.32
15.46
12.88
12.73
Revenue per Share
2.23
2.66
0.07
0.38
0.44
0.46
0.51
0.88
3.29
4.8
5.91
1.38
-0.82
-0.37
0.6
Basic EPS, GAAP
1.51
-0.06
-0.48
-0.33
-0.36
-0.24
0.4
0.85
2.12
2.46
2.38
1.11
0.99
1.66
- -
Free Cash Flow per Basic Share
0.33
0.59
0.07
0.08
0.08
0.09
0.09
0.19
0.2
0.37
1.31
1.8
0.9
0.88
0.9
Dividend per Share
9.2
11.81
19.01
2.39
2.83
3.72
4.16
4.97
8.24
13.54
18.48
17.84
15.81
14.53
13.98
Book Value per Share
8.73
11.26
18.23
2.34
2.64
3.49
3.92
4.76
7.91
13.36
18.09
17.41
15.33
14.04
13.52
Tangible Book Value per Share
20
20
458
346
386
410
457
457
459
462
466
466
465
468
463
Basic Weighted Avg Shares
977
1,356
1,838
2,389
3,222
3,792
4,525
5,269
8,244
11,943
15,476
8,540
7,190
6,030
5,895
Sales/Revenue/Turnover
7.03
6.57
3.45
8.2
7.06
8.04
7.95
9.44
23.02
24.07
23.24
11.49
6.64
4.02
5.87
Operating Margin (%)
28
36
48
68
126
174
225
257
281
426
528
571
554
414
- -
Depreciation Expense
44
52
31
131
170
189
233
402
1,510
2,220
2,755
643
-381
-173
280
Net Income, GAAP
23.83
28.66
23.28
24.03
19.28
23.44
20.38
16.23
13.09
13.98
14.33
13.96
- -
- -
17.99
Effective Tax Rate (%)
4.51
3.87
1.7
5.5
5.28
4.97
5.16
7.64
18.31
18.58
17.8
7.53
-5.3
-2.87
4.75
Profit Margin (%)
64
74
-4
336
464
900
924
1,146
2,358
4,202
6,079
5,576
5,086
4,571
4,299
Working Capital
5
5
203
233
472
537
499
359
512
421
347
448
633
668
680
LT Debt
204
258
392
960
1,134
1,744
1,956
2,326
3,877
6,523
8,877
8,547
7,475
6,859
6,620
Total Equity
- -
11.94
4.76
11.41
9.5
9.69
9.94
14.51
42.11
40.32
34.65
7.44
- -
- -
4.68
Return on Invested Capital (%)
- -
12.82
5.76
13.06
11.08
9.42
9.53
14.92
39.22
35.86
32.37
7.19
- -
- -
3.3
Return on Capital (%)
- -
25.28
10.27
20.14
16.75
13.45
12.94
19.25
49.81
43.99
36.88
7.57
-4.86
-2.47
4.21
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
154
168
173
LT Borrowings
589
575
553
LT Finance Leases
114
118
128
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
463
463
463
Market Capitalization
12,165
10,414
13,462

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
6,187
6,147
6,289
Cash, Cash Equivalents & STI
2,349
2,243
2,398
Accounts Receivable, Net
3,392
3,481
3,403
Inventories
183
186
202
Total Current Liabilities
1,978
1,962
1,990
Payables & Accruals
- -
- -
- -
ST Debt
154
168
173
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.95%
15.97%
-8.25%
Free Cash Flow
-1.96%
3.86%
69.26%
Net Income, GAAP
19.24%
-43.86%
-54.56%
Sales/Revenue/Turnover
14.25%
-0.46%
-16.12%
Total Cash Common Dividend
48.86%
65.97%
-1.35%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,841
2,040
1,738
1,571
7,190
2025
1,467
1,530
- -
1,492
6,030
2026
1,351
1,533
1,518
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.04
0.23
0.01
-1.03
-0.82
2025
-0.06
-0.12
- -
-0.2
-0.37
2026
0.09
0.32
0.4
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.88
- -
0.01
0.9
2025
0.89
0.01
- -
-0.01
0.88
2026
0.86
0.01
0.01
- -
- -
Business
Guangzhou Kingmed Diagnostics Group Co., Ltd. is a leading independent clinical laboratory services provider in China, founded in 1994 and headquartered in Guangzhou. The company offers comprehensive medical diagnostic services including clinical laboratory testing, pathology, molecular diagnostics, clinical biochemistry, and gene-based testing; it operates more than 200 laboratories and 50 centralized labs across China, covering over 90% of the population with over 4000 test items available. Additional services include clinical research, health management, cold chain logistics, forensic testing, and scientific research services, enhanced by investments in artificial intelligence and big data technologies. Kingmed serves over 23,000 medical institutions and conducts over 70 million tests annually, focusing on high-value tests such as genetic screening and tumor marker detection. Recent significant developments include strategic partnerships to expand Alzheimer's disease diagnostic testing access, collaborations to introduce advanced genomic oncology technologies such as comprehensive genomic tissue panels for cancer patients, and ongoing investments to improve cold chain logistics capabilities. The company has also focused on integrating digital transformation initiatives with partners like Huawei Cloud to enhance AI-assisted diagnostic screening processes. Guangzhou Kingmed Diagnostics continues to strengthen its position through innovation, technology adoption, and expansion within China's vast diagnostic market and collaborates with global organizations to advance its medical testing solutions. Its broad geographic footprint spans mainland China and Hong Kong, targeting hospitals, research institutions, biotechnology firms, and other healthcare providers.